Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
Genzyme, 8 Oct 2015
Accessed on 13 Oct 2015 from http://news.genzyme.com/press-release/treatment-effects-maintained-over-five-years-majority-patients-relapsing-remitting-mul.